Radionetics Oncology

Radionetics Oncology is focused on the discovery and development of novel precision radiopharmaceuticals for the treatment of a wide range of oncology indications. The company leverages Crinetics Pharmaceuticals’ core non-peptide, small molecule platform to direct therapeutic radioisotopes to selective peptide receptors expressed on tumors. Radionetics was co-founded by Crinetics, 5AM Ventures, and Frazier, and has launched with a pipeline of lead and drug candidates against multiple oncology targets.

Year of Investment
Life Sciences
San Diego, California